title: Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure.
abstract: Glucagon-like peptide-2 (GLP-2) is a nutrient-dependent, proglucagon-derived gut hormone that shows promise for the treatment of short bowel syndrome (SBS). Our objective was to investigate how combination GLP-2 + enteral nutrients (EN) affects intestinal adaption in a rat model that mimics severe human SBS and requires parenteral nutrition (PN). Male Sprague-Dawley rats were assigned to one of five groups and maintained with PN for 18 days: total parenteral nutrition (TPN) alone, TPN + GLP-2 (100 μg·kg(-1)·day(-1)), PN + EN + GLP-2(7 days), PN + EN + GLP-2(18 days), and a nonsurgical oral reference group. Animals underwent massive distal bowel resection followed by jejunocolic anastomosis and placement of jugular catheters. Starting on postoperative day 4, rats in the EN groups were allowed ad libitum access to EN. Groups provided PN + EN + GLP-2 had their rate of PN reduced by 0.25 ml/day starting on postoperative day 6. Groups provided PN + EN + GLP-2 demonstrated significantly greater body weight gain with similar energy intake and a safe 80% reduction in PN compared with TPN ± GLP-2. Groups provided PN + EN + GLP-2 for 7 or 18 days showed similar body weight gain, residual jejunal length, and digestive capacity. Groups provided PN + EN + GLP-2 showed increased jejunal GLP-2 receptor (GLP-2R), insulin-like growth factor-I (IGF-I), and IGF-binding protein-5 (IGFBP-5) expression. Treatment with TPN + GLP-2 demonstrated increased jejunal expression of epidermal growth factor. Cessation of GLP-2 after 7 days with continued EN sustained the majority of intestinal adaption and significantly increased expression of colonic proglucagon compared with PN + EN + GLP-2 for 18 days, and increased plasma GLP-2 concentrations compared with TPN alone. In summary, EN potentiate the intestinotrophic actions of GLP-2 by improving body weight gain allowing for a safe 80% reduction in PN with increased jejunal expression of GLP-2R, IGF-I, and IGFBP-5 following distal bowel resection in the rat.
authors: Department of Surgery, University of Wisconsin-Madison, USA.
authors: Adam S
authors: AS
authors: Brinkman
authors: Sangita G
authors: SG
authors: Murali
authors: Stacy
authors: S
authors: Hitt
authors: Patrick M
authors: PM
authors: Solverson
authors: Jens J
authors: JJ
authors: Holst
authors: Denise M
authors: DM
authors: Ney
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004750:Enteral Nutrition / Q000379:methods; D053767:Glucagon-Like Peptide 2 / Q000494:pharmacology*; D006801:Humans; D007334:Insulin-Like Growth Factor I; D007421:Intestine, Small / Q000378:metabolism*; D008297:Male; D008940:Mitotic Index; D010288:Parenteral Nutrition; D052336:Proglucagon / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D060888:Real-Time Polymerase Chain Reaction; D012778:Short Bowel Syndrome / Q000378:metabolism / Q000628:therapy*
chemical_list: D053767:Glucagon-Like Peptide 2; D052336:Proglucagon; D007334:Insulin-Like Growth Factor I